Home / Journals Clinical Neurology and Neuroscience / Molecular Target in CNS Malignancies
Molecular Target in CNS Malignancies
Submission Deadline: Nov. 25, 2019

This special issue currently is open for paper submission and guest editor application.

Join as Guest Editor Submit to Special Issue
Lead Guest Editor
Mingzhi Han
University of Bergen, Bergen, Norway
Guest Editors
  • Shuai Wang
    Shandong University, Jinan, China
  • Wenbo Zhao
    Shandong University, Jinan, China
  • Bin Huang
    Shandong University, Jinan, China
  • Ya Zhang
    Shandong University, Jinan, China
  • Yang Kong
    Shandong University, Jinan, China
  • Yuzhen Wei
    Jining Hospital, Jinan, China
Guidelines for Submission
Manuscripts can be submitted until the expiry of the deadline. Submissions must be previously unpublished and may not be under consideration elsewhere.
Papers should be formatted according to the guidelines for authors (see: http://www.sciencepublishinggroup.com/journal/guideforauthors?journalid=271). By submitting your manuscripts to the special issue, you are acknowledging that you accept the rules established for publication of manuscripts, including agreement to pay the Article Processing Charges for the manuscripts. Manuscripts should be submitted electronically through the online manuscript submission system at http://www.sciencepublishinggroup.com/login. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal and will be listed together on the special issue website.
Published Papers
The special issue currently is open for paper submission. Potential authors are humbly requested to submit an electronic copy of their complete manuscript by clicking here.

Special Issue Flyer (PDF)

Please download to know all details of the
Special Issue

Introduction
Human gliomas are the most common and deadly type of primary intracranial tumors and account for approximately 80% of all primary CNS malignancies. Gliomas are histopathologically classified into four tumor grades (I–IV) according to the World Health Organization (WHO). WHO grade IV or glioblastoma multiforme (GBM) confers the worst prognosis, with a median survival time of merely 12 to 15 months following primary diagnosis.
With advancement of gene technology, molecular signatures have become prominent in the classification of gliomas in recent years. Whole-genome analysis of patient cases through The Cancer Genome Atlas (TCGA), revealed a molecular classification scheme for GBM which includes four molecular subtypes: proneural, neural, classical, and mesenchymal. Among these four subtypes, the mesenchymal subtype was distinguished from the others as being particularly aggressive. Thus, there is an urgent need for the exploration of novel biomarkers and therapeutic targets for brain tumor, especially GBM.
The special issue “Molecular Target in CNS malignancies” aims to highlight the significant findings and advances in our understanding of the role of the novel molecular targets, diagnostic biomarkers as well as novel prognostic indicators in CNS malignancies, especially GBM.
The special issue “Molecular Target in CNS malignancies” will provide an important forum for exciting findings in Neuro-oncology-related research, presenting an unparalleled opportunity to communicate information to specialists and the public, opening new avenues for the understanding, prevention, diagnosis and treatment of brain tumor patients.

Aims and Scope:

  1. Molecular targeted therapies
  2. Prognostic indicators of CNS malignancies
  3. Clinical trials and pre-clinical studies of neuro-oncology
  4. Cancer antigens and immune checkpoint
  5. Molecular mechanisms of drug resistance in CNS malignancies
  6. RNA-seq and proteomics study of CNS malignancies
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186